Hepatitis D: Background, Etiology, Epidemiology (original) (raw)

Background

Hepatitis D virus (HDV) is an RNA virus that was discovered in 1977 and is structurally unrelated to the hepatitis A (HAV), hepatitis B (HBV), and hepatitis C (HCV) viruses. HDV causes a unique infection that requires the assistance of HBV viral particles to replicate and infect hepatocytes. [1, 2, 3, 4] Its clinical course is varied and ranges from acute, self-limited infection to acute, fulminant liver failure. Chronic liver infection can lead to end-stage liver disease and associated complications (including accelerated fibrosis, liver decompensation, and hepatocellular carcinoma). [5, 6, 7, 8, 9, 10]

There are three known genotypes of HDV. Genotype 1 has a worldwide distribution; genotype 2 exists in Taiwan, Japan, and northern Asia; and genotype 3 is found in South America.

Simultaneous coinfection with HBV and HDV occurs in 5-15% of those with HBV [8, 11] and results in fulminant liver failure in 1% of patients. HBV-HDV coinfection is the most aggressive form of viral hepatitis. [8, 12, 13] Complete clinical recovery and clearance of HBV and HDV coinfection is the most common outcome. (See Prognosis and Workup.)

Infection with HDV in a patient who is already positive for the hepatitis B surface antigen (HBsAg) is known as superinfection and results in fulminant liver failure in 5% of patients. Approximately 80-90% develop chronic HDV infection. These patients progress more rapidly to develop cirrhosis and may develop hepatocellular carcinoma. (See Workup.)

A study from The Netherlands suggested that HDV may hinder the control of HBV. Xiridou et al used a mathematical model for the transmission of both viruses and calculated the reproduction numbers of single HBV infections and dual HBV/HDV infections. [3] The investigators looked at the endemic prevalence of both viruses and found that HDV modulates HBV epidemic severity and also hampers the impact on HBV interventions. Xiridou et al concluded that in endemic populations with HDV, control programs that ignore HDV presence may lead to an underestimation of the HBV epidemic and an overestimation of positive results, as control of HBV is dependent on the reproduction numbers of dual HBV/HDV infections. [3] (See Epidemiology.)

See the following Medscape Drugs & Diseases topics for more information:

eMedicine Logo

Etiology

Hepatitis D virus (HDV) infection is an acute and chronic inflammatory process involving the liver. HDV is transmitted parenterally; it can replicate independently within the hepatocyte, but it requires hepatitis B surface antigen (HBsAg) for propagation. Hepatic cell death may occur due to the direct cytotoxic effect of HDV or via a host-mediated immune response.

Risk factors include intravenous drug use (IVDU) and multiple blood transfusions. A study of 652 North American patients infected with hepatitis B virus (HBV) found 91 with concurrent HDV infection; independent risk factors for HDV included the following [14] :

Sexual transmission is less efficient than with HBV.

Perinatal transmission is rare; no such cases have been reported in the United States.

eMedicine Logo

Epidemiology

Widespread vaccination against hepatitis B in developed nations has helped to reduce the incidence of HDV infection. [10] In the United States, hepatitis D virus (HDV) infection is observed more commonly among patients with a history of intravenous drug use and in persons from the Mediterranean basin.

Initial studies estimated approximately 15-20 million people are coinfected with HDV and HBV worldwide. [11, 15] More recent studies suggest that the global prevalence of HDV is probably two to three times higher than previously estimated. [11] Areas with the highest HDV prevalence include regions with high migration of populations from HDV endemic countries and less wealthy nations, [10] as well as southern Italy; North Africa; the Middle East; the Amazon Basin [16] ; and the American South Pacific islands of Samoa, Hauru, and Hiue. Although China, Japan, Taiwan, and Myanmar (formerly Burma) have a high prevalence of HBV infection, they have a low rate of HDV infection. [17, 18]

A 2017 case-control study from Northern Spain (1983-2012) that evaluated the prevalence and epidemiology of HDV infection among those infected with HBV found an 8.2% prevalence of anti-HDV. [19] In the analysis of patients grouped into years 1983-1997 (group A) and 1998-2012 (group B), the investigators noted that the prevalence of anti-HDV fell from 9.4% in the first group to 6.1% in the second group. Moreover, independent risk factors related to the presence of anti-HDV differed between the two groups, with intravenous drug use (IVDA), blood transfusion, and high alanine aminotransferase (ALT) levels affecting the earlier group, whereas immigration, IVDA, promiscuous sexual activity, and elevated ALT levels predominantly affected the latter group. [19]

HDV infection is more common in adults than in children. However, children from underdeveloped, HDV-endemic countries are more likely to contract HDV infection through breaks in the skin, due to the presence of skin lesions.

eMedicine Logo

Prognosis

The prognosis is excellent for patients with coinfection in whom treatment eradicates both viruses.

The prognosis is variable for patients who are superinfected. It depends on the duration and severity of hepatitis B virus (HBV) infection, alcohol consumption, comorbid illnesses, and age.

In patients who undergo liver transplantation for chronic liver disease secondary to HBV and hepatitis D virus (HDV) infections, HDV seems to suppress the replication of HBV in the transplanted liver and may help to prolong graft survival. However, fulminant hepatitis from recurrent HBV and HDV infections in the transplanted liver has resulted in patient death or the need to retransplant.

HBV-HDV superinfection significantly increases adult morbidity and mortality. [20] In a 2017 nationwide study that evaluated risk factors associated with chronic HBV infection in France (2008-2013), investigators noted that coinfection with HDV or HCV, alcohol use disorders, diabetes mellitus, and other rare causes of chronic liver disease all increased the risk of all-cause mortality, particularly following progression of liver disease. [12]

Complications

Complications of HDV infection may include the following:

eMedicine Logo

Patient Education

Educate patients regarding modification of high-risk behaviors, including intravenous drug use and unsafe sexual practices.

Promote the use of universal precautions for health care workers.

Discuss with patients with chronic hepatitis D virus (HDV) and hepatitis B virus (HBV) infections that they should not donate blood, share toothbrushes or razors, or consume alcohol. Precautions should be observed regarding blood and body fluids.

eMedicine Logo

  1. Rizzetto M, Verme G. Delta hepatitis--present status. J Hepatol. 1985. 1(2):187-93. [QxMD MEDLINE Link].
  2. Bean P. Latest discoveries on the infection and coinfection with hepatitis D virus. Am Clin Lab. 2002 Jun. 21(5):25-7. [QxMD MEDLINE Link].
  3. Xiridou M, Borkent-Raven B, Hulshof J, Wallinga J. How hepatitis D virus can hinder the control of hepatitis B virus. PLoS One. 2009. 4(4):e5247. [QxMD MEDLINE Link]. [Full Text].
  4. Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: a review. World J Hepatol. 2013 Dec 27. 5(12):666-75. [QxMD MEDLINE Link].
  5. Smedile A, Casey JL, Cote PJ, et al. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology. 1998 Jun. 27(6):1723-9. [QxMD MEDLINE Link].
  6. Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology. 1995 Feb. 21(2):333-9. [QxMD MEDLINE Link].
  7. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009 May. 136(5):1629-38. [QxMD MEDLINE Link].
  8. Bahcecioglu IH, Sahin A. Treatment of delta hepatitis: today and in the future - a review. Infect Dis (Lond). 2017 Apr. 49(4):241-50. [QxMD MEDLINE Link].
  9. Bockmann JH, Grube M, Hamed V, et al. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort. BMC Gastroenterol. 2020 Jan 30. 20(1):24. [QxMD MEDLINE Link]. [Full Text].
  10. Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021 May. 74(5):1200-11. [QxMD MEDLINE Link]. [Full Text].
  11. Vlachogiannakos J, Papatheodoridis GV. New epidemiology of hepatitis delta. Liver Int. 2020 Feb. 40 suppl 1:48-53. [QxMD MEDLINE Link].
  12. Mallet V, Hamed K, Schwarzinger M. Prognosis of patients with chronic hepatitis B in France (2008-2013): A nationwide, observational and hospital-based study. J Hepatol. 2017 Mar. 66(3):514-20. [QxMD MEDLINE Link].
  13. Alfaiate D, Lucifora J, Abeywickrama-Samarakoon N, et al. HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. Antiviral Res. 2016 Dec. 136:19-31. [QxMD MEDLINE Link].
  14. Da BL, Rahman F, Lai WC, Kleiner DE, Heller T, Koh C. Risk factors for delta hepatitis in a North American cohort: who should be screened?. Am J Gastroenterol. 2021 Jan 1. 116(1):206-9. [QxMD MEDLINE Link].
  15. Alfaiate D, Deny P, Durantel D. Hepatitis delta virus: from biological and medical aspects to current and investigational therapeutic options. Antiviral Res. 2015 Oct. 122:112-29. [QxMD MEDLINE Link].
  16. Braga WS, Castilho Mda C, Borges FG, et al. Hepatitis D virus infection in the Western Brazilian Amazon - far from a vanishing disease. Rev Soc Bras Med Trop. 2012 Dec. 45(6):691-5. [QxMD MEDLINE Link].
  17. Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009 Dec. 16(12):883-94. [QxMD MEDLINE Link].
  18. Makuwa M, Mintsa-Ndong A, Souquiere S, Nkoghe D, Leroy EM, Kazanji M. Prevalence and molecular diversity of hepatitis B virus and hepatitis delta virus in urban and rural populations in northern Gabon in central Africa. J Clin Microbiol. 2009 Jul. 47(7):2265-8. [QxMD MEDLINE Link]. [Full Text].
  19. Ordieres C, Navascues CA, Gonzalez-Dieguez ML, et al. Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from Northern Spain. Eur J Gastroenterol Hepatol. 2017 Mar. 29(3):277-83. [QxMD MEDLINE Link].
  20. Goyal A, Murray JM. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication. Theor Popul Biol. 2016 Dec. 112:60-9. [QxMD MEDLINE Link].
  21. Shah PA, Choudhry S, Reyes KJC, Lau DTY. An update on the management of chronic hepatitis D. Gastroenterol Rep (Oxf). 2019 Dec. 7(6):396-402. [QxMD MEDLINE Link]. [Full Text].
  22. Kodani M, Martin A, Mixson-Hayden T, Drobeniuc J, Gish RR, Kamili S. One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. J Virol Methods. 2013 Nov. 193(2):531-5. [QxMD MEDLINE Link].
  23. Buchmann B, Dohner K, Schirdewahn T, et al. A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. Antiviral Res. 2017 Feb 20. 141:116-23. [QxMD MEDLINE Link].
  24. European Medicines Agency. Hepcludex (EMEA/H/C/004854). Available at https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex. August 12, 2020. Updated: October 7, 2020; Accessed: January 25, 2021.
  25. Highleyman L. Bulevirtide shows promise as maintenance therapy for hepatitis D. InfoHep.org. August 30, 2020. Available at https://www.infohep.org/page/3549039.
  26. Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016 Oct. 65(4):835-48. [QxMD MEDLINE Link].
  27. Abeywickrama-Samarakoon N, Cortay JC, Deny P. The hepatitis D satellite virus of hepatitis B virus: half-opening a new era to control viral infection?. Curr Opin Infect Dis. 2016 Dec. 29(6):645-53. [QxMD MEDLINE Link].
  28. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011 Jan 27. 364(4):322-31. [QxMD MEDLINE Link].
  29. Samiullah S, Bikharam D, Nasreen. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol. 2012 Oct 28. 18(40):5793-8. [QxMD MEDLINE Link].
  30. Abdrakhman A, Ashimkhanova A, Almawi WY. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis. Antiviral Res. 2021 Jan. 185:104995. [QxMD MEDLINE Link].
  31. Maravelia P, Frelin L, Ni Y, et al. Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections. J Infect Dis. 2021 Jan 4. 223(1):128-38. [QxMD MEDLINE Link]. [Full Text].
  32. Deterding K, Wedemeyer H. Beyond pegylated Interferon-alpha: new treatments for hepatitis delta. AIDS Rev. 2019. 21(3):126-34. [QxMD MEDLINE Link].
  33. Manesis EK, Schina M, Le Gal F, et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther. 2007. 12(3):381-8. [QxMD MEDLINE Link].
  34. Suvak B, Dulger AC, Suvak O, Yesilyurt AO, Gultepe B, Guducuoglu H. The prevalence and impact of brucellosis in patients with hepatitis delta virus infection: inside the Brucella outbreak with cirrhosis. Arch Med Sci. 2017 Mar 1. 13(2):377-82. [QxMD MEDLINE Link]. [Full Text].
  35. Gu XH, Chen Z, Dai RY, et al. Analysis on the clinical features of 507 HDV-infected patients. Cell Biochem Biophys. 2014 Dec. 70(3):1829-32. [QxMD MEDLINE Link].
  36. Huang CR, Lo SJ. Hepatitis D virus infection, replication and cross-talk with the hepatitis B virus. World J Gastroenterol. 2014 Oct 28. 20(40):14589-97. [QxMD MEDLINE Link]. [Full Text].
  37. Keskin O, Wedemeyer H, Tuzun A, et al. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. Clin Gastroenterol Hepatol. 2015 Dec. 13(13):2342-49.e1-2. [QxMD MEDLINE Link].

Author

Coauthor(s)

Chief Editor

Acknowledgements

David Eric Bernstein, MD Director of Hepatology, North Shore University Hospital; Professor of Clinical Medicine, Albert Einstein College of Medicine

David Eric Bernstein, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment